Infant Bacterial Therapeutics AB announced that the Mexican Patent Office has granted a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III. The ambition for IBP-9414 is to become approved probiotical drug with the goal to prevent life threatening diseases in premature infants including NEC and sepsis by promoting healthy stomach-and bowel development in premature infants. The invention covers a novel way to activate the freeze-dried bacteria and corresponding patent applications are currently pending in additional future key markets including the US and Europe. This patent increases the existing protection of IBTs drug candidate IBP-9414 in addition to Orphan Drug Exclusivity and biological data protection already established in the US and EU. The Mexican patent provides coverage until 2036. IBP-9414 is intended to be marketed in Mexico once marketing authorization has been obtained.